Clozaril U.S. Generic Penetration "Almost Nil" - Novartis' Karabelas
Executive Summary
Novartis has seen little effect on Clozaril U.S. market share nearly four months after the introduction of the first generic clozapine in the U.S., Novartis Pharmaceuticals CEO Jerry Karabelas reported at a March 17 review of the firm's 1997 results in London.